Outcomes of a novel thin-strut bioresorbable-polymer sirolimus-eluting stent in patients with chronic total occlusions: A multicenter registry

Lorenzo Azzalini, Ozan M Demir, Gabriele L Gasparini, Luca Grancini, Alessio La Manna, Soledad Ojeda, Susanna Benincasa, Barbara Bellini, Enrico Poletti, Davide Maccagni, Margherita Soldi, Loredana Iannetta, Daniela Trabattoni, Giacomo Gravina, Francisco Hidalgo, Francesco Giannini, Manuel Pan, Corrado Tamburino, Antonio L Bartorelli, Bernhard ReimersCosmo Godino, Mauro Carlino, Antonio Colombo

Research output: Contribution to journalArticlepeer-review


BACKGROUND: We aimed to evaluate the mid-term outcomes of a novel thin-strut bioresorbable-polymer sirolimus-eluting stent (BP-SES) in chronic total occlusion (CTO) percutaneous coronary intervention (PCI), as compared with durable-polymer everolimus-eluting stents (EES).

METHODS: We compiled a multicenter registry of patients undergoing CTO recanalization followed by BP-SES or EES implantation. The primary endpoint was the incidence of target-lesion failure (TLF, a composite of cardiac death, target-vessel myocardial infarction, and target-lesion revascularization) at one year. Propensity score matching (PSM) was used to adjust for case mix.

RESULTS: Overall, 413 patients were included (BP-SES n = 242, EES n = 171). PSM resulted in 131 matched pairs, which represented the subject of the main analysis. Antegrade wire escalation was the most successful crossing technique (66% vs. 63%, p = 0.98) in both the BP-SES and EES groups, respectively. Procedural success rates were similar between groups (BP-SES 96% vs. EES 93%, p = 0.24). At one-year follow-up, there were no differences in the primary endpoint of TLF (5.7% vs. 8.3%, p = 0.44), and in cardiac death (0.9% vs. 2.8%, p = 0.32), target-vessel myocardial infarction (0.9% vs 1.9%, p = 0.57), target-lesion revascularization (3.7% vs 3.7%, p = 0.99), or stent thrombosis (0.9% vs. 1.9%, p = 0.57), in BP-SES vs. EES, respectively.

CONCLUSIONS: Patients undergoing CTO PCI with BP-SES suffer a low rate of TLF at one-year follow-up, which is similar to that of subjects treated with durable-polymer EES.

Original languageEnglish
Pages (from-to)36-41
Number of pages6
JournalInternational Journal of Cardiology
Publication statusPublished - May 1 2018


  • Absorbable Implants/trends
  • Aged
  • Chronic Disease
  • Coronary Occlusion/diagnostic imaging
  • Drug-Eluting Stents/trends
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Percutaneous Coronary Intervention/methods
  • Polymers/administration & dosage
  • Registries
  • Sirolimus/administration & dosage
  • Treatment Outcome


Dive into the research topics of 'Outcomes of a novel thin-strut bioresorbable-polymer sirolimus-eluting stent in patients with chronic total occlusions: A multicenter registry'. Together they form a unique fingerprint.

Cite this